Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome

Y. J. Lin, T. F. Yeh, H. C. Lin, J. M. Wu, C. H. Lin, C. Y. Yu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of dexamethasone therapy on calcium homeostasis and bone growth were evaluated in 49 infants (24 placebo and 25 dexamethasone) who participated in a double-blind trial of early dexamethasone therapy for the prevention of chronic lung disease. Dexamethasone (0.25 mg kg-1 b.i.d. on d 1-7; mg kg-1 b.i.d. on d 8-14; 0.05 mg kg-1 b.i.d. on d 15-21; 0.02 mg kg- 1 b.i.d. on d 22-28) or saline placebo was given i.v. Serum calcium (Ca), phosphorus (P) and parathyroid hormone (PTH), and the corresponding urinary excretion of calcium (FE(Ca)) and phosphorus (FE(p)) were measured on d 2, 3, 7, 10, 14, 21 and 28 after starting the study. Radiographic evaluations of bone growth were also evaluated. Infants in the dexamethasone group had significantly higher PTH on d 2 (p < 0.01), 7 and 14 (p < 0.05) than infants in the placebo group. The dexamethasone-treated infants also had significantly higher FE(p) on d 2, 7 and 14 (p < 0.05) and lower FE(Ca) on d 7 and 14 (p < 0.05) than control infants. There was no significant difference between the groups in bone growth during the study. It was concluded that early dexamethasone therapy causes a transient elevation in PTH without apparent change in bone growth. The long-term effect remains to be evaluated further.

Original languageEnglish
Pages (from-to)1061-1065
Number of pages5
JournalActa Paediatrica, International Journal of Paediatrics
Volume87
Issue number10
DOIs
Publication statusPublished - Oct 28 1998
Externally publishedYes

Fingerprint

Newborn Respiratory Distress Syndrome
Bone Development
Premature Infants
Dexamethasone
Homeostasis
Calcium
Parathyroid Hormone
Placebos
Secondary Prevention
Phosphorus
Therapeutics
Lung Diseases
Chronic Disease
Serum

Keywords

  • Calcium homeostasis dexamethasone
  • Parathyroid hormone
  • Preterm infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. / Lin, Y. J.; Yeh, T. F.; Lin, H. C.; Wu, J. M.; Lin, C. H.; Yu, C. Y.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 87, No. 10, 28.10.1998, p. 1061-1065.

Research output: Contribution to journalArticle

@article{3d8744330700450aa27fc9005317e3b7,
title = "Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome",
abstract = "The effects of dexamethasone therapy on calcium homeostasis and bone growth were evaluated in 49 infants (24 placebo and 25 dexamethasone) who participated in a double-blind trial of early dexamethasone therapy for the prevention of chronic lung disease. Dexamethasone (0.25 mg kg-1 b.i.d. on d 1-7; mg kg-1 b.i.d. on d 8-14; 0.05 mg kg-1 b.i.d. on d 15-21; 0.02 mg kg- 1 b.i.d. on d 22-28) or saline placebo was given i.v. Serum calcium (Ca), phosphorus (P) and parathyroid hormone (PTH), and the corresponding urinary excretion of calcium (FE(Ca)) and phosphorus (FE(p)) were measured on d 2, 3, 7, 10, 14, 21 and 28 after starting the study. Radiographic evaluations of bone growth were also evaluated. Infants in the dexamethasone group had significantly higher PTH on d 2 (p < 0.01), 7 and 14 (p < 0.05) than infants in the placebo group. The dexamethasone-treated infants also had significantly higher FE(p) on d 2, 7 and 14 (p < 0.05) and lower FE(Ca) on d 7 and 14 (p < 0.05) than control infants. There was no significant difference between the groups in bone growth during the study. It was concluded that early dexamethasone therapy causes a transient elevation in PTH without apparent change in bone growth. The long-term effect remains to be evaluated further.",
keywords = "Calcium homeostasis dexamethasone, Parathyroid hormone, Preterm infant",
author = "Lin, {Y. J.} and Yeh, {T. F.} and Lin, {H. C.} and Wu, {J. M.} and Lin, {C. H.} and Yu, {C. Y.}",
year = "1998",
month = "10",
day = "28",
doi = "10.1080/080352598750031383",
language = "English",
volume = "87",
pages = "1061--1065",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome

AU - Lin, Y. J.

AU - Yeh, T. F.

AU - Lin, H. C.

AU - Wu, J. M.

AU - Lin, C. H.

AU - Yu, C. Y.

PY - 1998/10/28

Y1 - 1998/10/28

N2 - The effects of dexamethasone therapy on calcium homeostasis and bone growth were evaluated in 49 infants (24 placebo and 25 dexamethasone) who participated in a double-blind trial of early dexamethasone therapy for the prevention of chronic lung disease. Dexamethasone (0.25 mg kg-1 b.i.d. on d 1-7; mg kg-1 b.i.d. on d 8-14; 0.05 mg kg-1 b.i.d. on d 15-21; 0.02 mg kg- 1 b.i.d. on d 22-28) or saline placebo was given i.v. Serum calcium (Ca), phosphorus (P) and parathyroid hormone (PTH), and the corresponding urinary excretion of calcium (FE(Ca)) and phosphorus (FE(p)) were measured on d 2, 3, 7, 10, 14, 21 and 28 after starting the study. Radiographic evaluations of bone growth were also evaluated. Infants in the dexamethasone group had significantly higher PTH on d 2 (p < 0.01), 7 and 14 (p < 0.05) than infants in the placebo group. The dexamethasone-treated infants also had significantly higher FE(p) on d 2, 7 and 14 (p < 0.05) and lower FE(Ca) on d 7 and 14 (p < 0.05) than control infants. There was no significant difference between the groups in bone growth during the study. It was concluded that early dexamethasone therapy causes a transient elevation in PTH without apparent change in bone growth. The long-term effect remains to be evaluated further.

AB - The effects of dexamethasone therapy on calcium homeostasis and bone growth were evaluated in 49 infants (24 placebo and 25 dexamethasone) who participated in a double-blind trial of early dexamethasone therapy for the prevention of chronic lung disease. Dexamethasone (0.25 mg kg-1 b.i.d. on d 1-7; mg kg-1 b.i.d. on d 8-14; 0.05 mg kg-1 b.i.d. on d 15-21; 0.02 mg kg- 1 b.i.d. on d 22-28) or saline placebo was given i.v. Serum calcium (Ca), phosphorus (P) and parathyroid hormone (PTH), and the corresponding urinary excretion of calcium (FE(Ca)) and phosphorus (FE(p)) were measured on d 2, 3, 7, 10, 14, 21 and 28 after starting the study. Radiographic evaluations of bone growth were also evaluated. Infants in the dexamethasone group had significantly higher PTH on d 2 (p < 0.01), 7 and 14 (p < 0.05) than infants in the placebo group. The dexamethasone-treated infants also had significantly higher FE(p) on d 2, 7 and 14 (p < 0.05) and lower FE(Ca) on d 7 and 14 (p < 0.05) than control infants. There was no significant difference between the groups in bone growth during the study. It was concluded that early dexamethasone therapy causes a transient elevation in PTH without apparent change in bone growth. The long-term effect remains to be evaluated further.

KW - Calcium homeostasis dexamethasone

KW - Parathyroid hormone

KW - Preterm infant

UR - http://www.scopus.com/inward/record.url?scp=0031694503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031694503&partnerID=8YFLogxK

U2 - 10.1080/080352598750031383

DO - 10.1080/080352598750031383

M3 - Article

C2 - 9825973

AN - SCOPUS:0031694503

VL - 87

SP - 1061

EP - 1065

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 10

ER -